| 000 | 01075 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250513095204.0 | ||
| 264 | 0 | _c19960920 | |
| 008 | 199609s 0 0 eng d | ||
| 022 | _a0008-5472 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStone, S | |
| 245 | 0 | 0 |
_aReversible, p16-mediated cell cycle arrest as protection from chemotherapy. _h[electronic resource] |
| 260 |
_bCancer research _cJul 1996 |
||
| 300 |
_a3199-202 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCarrier Proteins _xpharmacology |
| 650 | 0 | 4 |
_aCell Cycle _xdrug effects |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 | _aCyclin-Dependent Kinase Inhibitor p16 |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 650 | 0 | 4 |
_aVinblastine _xadministration & dosage |
| 700 | 1 | _aDayananth, P | |
| 700 | 1 | _aKamb, A | |
| 773 | 0 |
_tCancer research _gvol. 56 _gno. 14 _gp. 3199-202 |
|
| 999 |
_c8760968 _d8760968 |
||